Artykuł w czasopiśmie
Brak miniatury
Licencja

CC-BYCC-BY - Uznanie autorstwa

Mechanochemical Formation of Racemic Praziquantel Hemihydrate with Improved Biopharmaceutical Properties

Autor
Jones, William
Zanolla, Debora
Keiser, Jennifer
Schneider-Rauber, Gabriela
Arhangelskis, Mihails
Hasa, Dritan
Chierotti, Michele R.
Voinovich, Dario
Perissutti, Beatrice
Data publikacji
2020
Abstrakt (EN)

Praziquantel (PZQ) is the first-line drug used against schistosomiasis, one of the most common parasitic diseases in the world. A series of crystalline structures including two new polymorphs of the pure drug and a series of cocrystals of PZQ have been scovered and deposited in the Cambridge Structural Database (CSD). This work adds to the list of ulticomponent forms ofPZQa relevant example of a racemic mihydrate (PZQ-HH), obtainable fromcommercialPZQ(polymorphic Form A) through chanochemistry. Noteworthy, the formation of the new hemihydrate strongly depends on the initial polymorphic form of PZQ and on the experimental conditions used. The new PZQ-HH has been fully characterized by means of HPLC, Dierential Scanning Calorimetry (DSC), Thermogravimetric Analysis (TGA), Hot-Stage Microscopy (SEM), Powder X-Ray Diraction (PXRD), Scanning Electron Microscopy (SEM), FT-IR, olarimetry, solid-state NMR (SS-NMR), solubility and intrinsic dissolution rate (IDR), and in vitro tests on Schistosoma mansoni adults. The crystal structure was solved from the powder X-ray diraction pattern and validated by periodic-DFT calculations. The new bioactive hemihydrate was physically stable for three months and showed eculiar biopharmaceutical features including enhanced solubility and a double ntrinsic ssolution rate in water in comparison to the commercially available PZQ Form A.

Słowa kluczowe EN
praziquantel
hemihydrate
mechanochemistry
neat grinding
liquid-assisted grinding
racemic compound
polymorphism
crystal structure solution
Dyscyplina PBN
nauki chemiczne
Czasopismo
Pharmaceutics
Tom
12
Zeszyt
3
Strony od-do
289
ISSN
1999-4923
Data udostępnienia w otwartym dostępie
2020-03-23
Licencja otwartego dostępu
Uznanie autorstwa